Diagnosis and treatment of migraine: an analysis of the latest diagnostic and therapeutic guidelines
DOI:
https://doi.org/10.12775/JEHS.2024.74.51722Keywords
botulinum neurotoxin, non-steroidal anti-inflammatory drugs, migraine, triptansAbstract
Introduction
Migraine is a common disease that a large part of the population struggles with. Stressful work and poor eating habits increase the risk of headaches. The basic therapy is lifestyle change, and when this does not bring results, medications are used. The choice of the appropriate preparation depends on the characteristics of the pain and the patient's condition. Knowledge about different treatment methods can improve patients' lives.
Aim of the study
The aim of the article was to present current guidelines for migraine therapy depending on the individual patient's requirements.
Materials and methods
The article is the result of a review of recent scientific literature using PubMed, Scopus and Google Scholar databases. The literature was reviewed using the keywords.
Results
Many clinical trials have examined the effects of different classes of drugs on migraine headaches. The final effect depends on the dose used, the moment of drug administration, and the patient's age, gender and health condition. Doctors often have to modify therapy within the same group of drugs to find a drug that will work for a given patient.
Conclusions
Clinical trials have proven the effectiveness of, among others, non-steroidal anti-inflammatory drugs, triptans and botulinum neurotoxin. A clinically significant analgesic effect is sometimes characterized by side effects, therefore careful selection of the preparation and patient observation are important.
References
Stępień A. Modern migraine treatment. Ból. 2019;20(1):39-44.
Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. doi:10.1016/j.aprim.2021.102208.
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23-S34.
Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg AMJM, Dodick DW. Migraine. Nat Rev Dis Primers. 2022;8(1):2. Published 2022 Jan 13. doi:10.1038/s41572-021-00328-4.
Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174-182. doi:10.1016/S1474-4422(17)30435-0.
Ailani J. Acute Migraine Treatment. Continuum (Minneap Minn). 2021;27(3):597-612. doi:10.1212/CON.0000000000000956.
Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022;21(10):911-921. doi:10.1016/S1474-4422(22)00211-3.
Haghdoost F, Togha M. Migraine management: Non-pharmacological points for patients and health care professionals. Open Med (Wars). 2022;17(1):1869-1882. Published 2022 Nov 23. doi:10.1515/med-2022-0598.
Tepper SJ. Acute Treatment of Migraine. Neurol Clin. 2019;37(4):727-742. doi:10.1016/j.ncl.2019.07.006.
Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. Med Clin North Am. 2019;103(2):215-233. doi:10.1016/j.mcna.2018.10.003.
Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015;55(6):778-793. doi:10.1111/head.12550.
Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action [published correction appears in Neurotherapeutics. 2018 Jan 8;:]. Neurotherapeutics. 2018;15(2):274-290. doi:10.1007/s13311-017-0592-1.
Vgontzas A, Pavlović JM. Sleep Disorders and Migraine: Review of Literature and Potential Pathophysiology Mechanisms. Headache. 2018;58(7):1030-1039. doi:10.1111/head.13358.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(10):e2128544. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.28544.
Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg AMJM, Dodick DW. Migraine. Nat Rev Dis Primers. 2022;8(1):2. Published 2022 Jan 13. doi:10.1038/s41572-021-00328-4.
Jastrzębski K. Tryptany w migrenowych bólach głowy - bilans korzyści i ryzyka. Aktualn Neurol. 2017;17(2).
Ala M, Ghasemi M, Mohammad Jafari R, Dehpour AR. Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review. Drug Dev Res. 2021;82(7):896-906. doi:10.1002/ddr.21819.
Menshawy A, Ahmed H, Ismail A, Abushouk AI, Ghanem E, Pallanti R, Negida A. Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. Neurol Sci. 2018;39(1):31-44. doi:10.1007/s10072-017-3119-y.
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55 Suppl 4:221-235. doi:10.1111/head.12601.
Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, Martelletti P. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016;9(5):414-423. doi:10.1177/1756285616650619.
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499.
MacGregor EA. A review of frovatriptan for the treatment of menstrual migraine. Int J Womens Health. 2014;6:523-535. Published 2014 May 21. doi:10.2147/IJWH.S63444.
Allais G, Benedetto C. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. Drug Des Devel Ther. 2016;10:3225-3236. Published 2016 Oct 3. doi:10.2147/DDDT.S105932.
Allais G, Benedetto C. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. Drug Des Devel Ther. 2016;10:3225-3236. Published 2016 Oct 3. doi:10.2147/DDDT.S105932.
Pascual J, Vila C. Almotriptan: a review of 20 years' clinical experience. Expert Rev Neurother. 2019;19(8):759-768. doi:10.1080/14737175.2019.1591951.
Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017;57(2):194-208. doi:10.1111/head.12978.
Vandenbussche N, Pisarek K, Paemeleire K. Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. J Headache Pain. 2023;24(1):75. Published 2023 Jun 22. doi:10.1186/s10194-023-01611-3.
Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;2014(5):CD008616. Published 2014 May 21. doi:10.1002/14651858.CD008616.pub2.
Diener HC, May A. Drug Treatment of Cluster Headache. Drugs. 2022;82(1):33-42. doi:10.1007/s40265-021-01658-z.
Tepper SJ, Chen S, Reidenbach F, Rapoport AM. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013;53 Suppl 2:62-71. doi:10.1111/head.12181.
Tfelt-Hansen P. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. Cephalalgia. 2021;41(14):1499-1505. doi:10.1177/03331024211028959.
Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain. 2011;12(4):399-403. doi:10.1007/s10194-011-0327-3.
Macone AE, Perloff MD. Triptans and migraine: advances in use, administration, formulation, and development. Expert Opin Pharmacother. 2017;18(4):387-397. doi:10.1080/14656566.2017.1288721.
Diener HC, May A. Drug Treatment of Cluster Headache. Drugs. 2022;82(1):33-42. doi:10.1007/s40265-021-01658-z.
Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ. 2014;348:g2285. Published 2014 Apr 7. doi:10.1136/bmj.g2285.
Hou M, Liu H, Li Y, Xu L, He Y, Lv Y, Zheng Q, Li L. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Eur J Clin Pharmacol. 2019;75(10):1369-1378. doi:10.1007/s00228-019-02748-4.
Yi KH, Lee JH, Hu HW, Kim HJ. Anatomical Proposal for Botulinum Neurotoxin Injection for Glabellar Frown Lines. Toxins (Basel). 2022;14(4):268. Published 2022 Apr 10. doi:10.3390/toxins14040268.
Thaker H, Zhang S, Diamond DA, Dong M. Beyond botulinum neurotoxin A for chemodenervation of the bladder. Curr Opin Urol. 2021;31(2):140-146. doi:10.1097/MOU.0000000000000843.
Yeung W, Richards AL, Novakovic D. Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia. Toxins (Basel). 2022;14(12):844. Published 2022 Dec 1. doi:10.3390/toxins14120844.
Serrera-Figallo MA, Ruiz-de-León-Hernández G, Torres-Lagares D, Castro-Araya A, Torres-Ferrerosa O, Hernández-Pacheco E, Gutierrez-Perez JL. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins (Basel). 2020;12(2):112. Published 2020 Feb 11. doi:10.3390/toxins12020112.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Joanna Cieszkowska, Karina Otręba, Karolina Czupryńska, Piotr Daniel, Michał Leśkiewicz, Justyna Aleksandra Składanek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 445
Number of citations: 0